Eli Lilly and Company leads structurally, with profitability as the clearest single gap between the two profiles. Halozyme Therapeutics still leads on growth and valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The comparison is mainly decided in profitability, with the rest of the profile carrying less weight. The overall score gap is 9 points in favour of Eli Lilly and Company.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
The match is driven mainly by capital structure and margin trend.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in profitability.
Left means cheaper relative valuation. Higher means stronger structure.
Eli Lilly and Company is cheaper, but Halozyme Therapeutics, Inc. is still stronger.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where HALO and LLY each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 15.2-point ROIC advantage.
Absolute pricing still looks more supportive for Halozyme Therapeutics, with a forward P/E that is 15.1 turns lower there.
The profitability edge is decisive, even though current pricing and valuation still lean somewhat toward Halozyme Therapeutics, Inc..
Break down the HALO vs LLY comparison across all dimensions with the full interactive tool.
Explore how HALO and LLY each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.